查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1862931

多重檢測免疫檢測市場：按技術、產品、最終用戶和應用分類 - 全球預測（2025-2032 年）

Multiplex Detection Immunoassays Market by Technology, Product, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，多重檢測免疫檢測市場將成長至 39.1 億美元，複合年成長率為 7.12%。

主要市場統計數據
基準年 2024 22.5億美元
預計年份：2025年 24.1億美元
預測年份：2032年 39.1億美元
複合年成長率 (%) 7.12%

關於多重檢測免疫檢測的權威報告：技術整合、臨床應用和相關人員期望塑造策略重點的框架

多重檢測免疫檢測技術已發展成為現代轉化研究、臨床診斷和治療開發的基礎。檢測小型化、試劑化學和數據分析技術的進步，使得從極少量樣本中同時檢測多種分析物成為可能，在提高通量的同時，也保留了生物學背景資訊。這些技術對於生物標記發現、免疫分析和多重臨床檢測至關重要，因為多維度的結果可以提高診斷特異性，並對患者群體進行分層，從而指導標靶治療。

技術整合、工作流程整合和生態系統協作將如何重新定義多重免疫檢測領域的競爭格局和應用管道

過去五年，在技術創新融合和終端用戶需求變化的推動下，多重檢測免疫檢測領域經歷了變革性發展。從單分析物檢測到高密度微珠、平面陣列和微陣列技術的轉變，加速了該技術從研發階段到臨床應用的進程。基於流式細胞技術的系統和以微珠為基礎的平台的改進提高了靈敏度和動態範圍，而微陣列和平面陣列技術則實現了高密度探針架構，從而能夠在有限的樣本量內捕獲更廣泛的分析物特徵。

評估截至2025年的關稅調整如何影響免疫檢測價值鏈中的籌資策略、供應鏈韌性和生產本地化決策。

美國在2025年前實施的一系列貿易措施和關稅調整，為多重免疫檢測價值鏈中的供應商和終端用戶帶來了複雜的挑戰。關稅變化正在影響進口儀器、試劑盒和關鍵原料的相對成本結構，進而影響製造商、經銷商和臨床檢查室的籌資策略。採用地域多元化製造地和採購策略的供應商更有能力應對近期成本波動。同時，依賴單一區域供應鏈的公司正面臨營運壓力，迫使它們重新評估供應商合約並調整定價模式。

透過綜合分析技術類型、產品系列、最終用戶需求和臨床應用，幫助確定打入市場策略。

要了解多重偵測免疫檢測市場的模組化結構，就需要清楚了解定義競爭格局和應用場景邊界的關鍵技術、產品、終端用戶和應用維度。從技術角度來看，以微珠為基礎的免疫檢測、基於流式細胞技術的免疫檢測、基於微陣列的免疫檢測和平面陣列免疫檢測之間的區別至關重要，因為每種形式在通量、靈敏度、多重密度和工作流程相容性方面都各有重點。這些技術選擇會影響產品設計和下游服務需求。

影響美洲、歐洲、中東和非洲以及亞太地區採用、分銷和監管管道的關鍵區域趨勢和戰略考量

區域趨勢對多重免疫檢測的技術應用、分銷模式和監管管道產生了深遠影響，美洲、歐洲、中東和非洲以及亞太地區呈現出截然不同的模式。在美洲，強大的學術網路、完善的臨床檢測基礎設施和蓬勃發展的生物技術產業推動了新型檢測方法和整合平台的早期應用。採購實踐往往側重於檢驗的工作流程和強大的售後支持，這促使供應商提供全面的服務包和本地化的技術支援。

深入了解推動差異化並在此領域創造整合價值提案的企業策略、夥伴關係模式和能力投資

多重免疫檢測領域的競爭格局由儀器製造商、試劑專家、軟體創新者和整合解決方案提供者組成，他們在整個價值鏈上既相互競爭又相互合作。領先的儀器供應商在分析性能、通量和整合便利性方面脫穎而出，而試劑和試劑盒供應商則專注於檢測特異性、批間一致性和法規文件，以支援臨床和研究應用。軟體供應商和服務供應商在將原始檢測結果轉化為檢驗、可重複的洞察以及透過雲端分析和強大的品管模組實現可擴展部署方面發揮著越來越重要的作用。

領導者需應對的實際策略挑戰，以增強平台模組化、供應鏈韌性、監管準備和夥伴關係主導的商業化。

產業領導者應採取審慎措施，以增強自身競爭優勢、推動產品應用並管控營運風險。首先，應優先開發模組化平台，實現逐步升級和不同檢測方法之間的交叉相容。這有助於降低顧客轉換成本，提升產品生命週期價值。模組化硬體結合檢驗的試劑盒和可互通的數據分析軟體，將能夠提供與終端用戶工作流程相契合的差異化解決方案。

為了支持這些發現，我們採用了嚴謹的混合方法研究方法，結合了專家訪談、文獻檢驗和跨區域檢驗，以得​​出可靠的研究結果。

支持這些發現的研究採用了多層次的調查方法，以確保結論的穩健性和可重複性。對主要技術文獻、監管指南和已發表的臨床檢驗研究進行全面回顧，為技術性能特徵和應用適用性奠定了證據基礎。此外，還對包括實驗室主任、檢測方法開發科學家、採購人員以及平台和試劑軟體供應商的高級管理人員在內的利益相關人員進行了結構化的訪談，以了解實際營運情況和戰略意圖，從而補充了上述二手研究。

總之，我們的綜合分析確定了多重解決方案永續採用所需的關鍵組合：檢驗的性能、證據生成和營運彈性。

累積分析揭示了技術成熟度、臨床需求和商業性結構調整的交匯點。多重檢測免疫檢測已從小眾研究工具發展成為廣泛適用的平台，支持藥物發現、轉化研究以及日益嚴苛的臨床應用。技術多樣性——以微珠為基礎、流式細胞技術、微陣列和平面陣列的方法——為根據通量、靈敏度和檢體限制客製化解決方案指明了方向。同時，儀器、試劑盒和軟體服務的產品細分也明確了商業化優勢。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將微流體平台整合到照護現場診斷中，用於高通量多重免疫檢測
  • 在臨床研究中採用新型螢光條碼技術同時檢測多種細胞激素
  • 人工智慧驅動的數據分析軟體的出現，增強了多重檢測結果的解讀和預測性生物標記的發現。
  • 利用磁性奈米粒子開發以微珠為基礎的多重免疫檢測方法，用於食品安全領域的病原體快速篩檢
  • 標準化校準方法對於提高不同平台多重檢測結果的重現性變得越來越重要。
  • 利用數位ELISA技術對多重檢測中低表現蛋白生物標記進行超靈敏檢測
  • 擴展單細胞多重免疫檢測，以實現自體免疫疾病研究中全面的免疫分析
  • 在遠端醫療環境中整合基於智慧型手機的成像模組，用於攜帶式多重免疫檢測讀數。
  • 生物技術公司與學術機構合作開發通用檢測平台，該平台可容納多種分析標靶。
  • 監管機構日益重視多重檢測檢驗標準，以確保其臨床效用和病人安全。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 多重檢測免疫檢測市場（依技術分類）

  • 以微珠為基礎的免疫檢測
  • 基於流式細胞技術的免疫檢測
  • 基於微陣列的免疫檢測
  • 平面陣列免疫檢測測定

9. 多重檢測免疫檢測市場（依產品分類）

  • 裝置
    • 分析器
    • 流式細胞儀
    • 領導者
  • 試劑盒和試劑
    • 檢測珠
    • 檢測抗體
    • 微陣列
    • 多重檢測試劑盒
  • 軟體和服務
    • 檢測開發服務
    • 數據分析軟體
    • 支援與維護

10. 多重檢測免疫檢測市場（依最終用戶分類）

  • 學術研究機構
  • CRO（受託研究機構）
  • 醫院和診斷實驗室
  • 製藥和生物技術公司

11. 多重檢測免疫檢測市場（按應用分類）

  • 自體免疫疾病
    • 發炎性腸道疾病
    • 類風濕性關節炎
    • 全身性紅斑性狼瘡
  • 心血管疾病
    • 動脈粥狀硬化
    • 心臟衰竭
    • 高血壓
  • 感染疾病
    • 細菌感染疾病
      • 大腸桿菌
      • 沙門氏菌
      • 結核
    • 寄生蟲感染疾病
      • 瘧疾
      • 血吸蟲病
      • 弓形蟲病
    • 病毒感染疾病
      • 肝炎
      • HIV
      • 流感
  • 神經病學
    • 阿茲海默症
    • 多發性硬化症
    • 帕金森氏症
  • 腫瘤學
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 攝護腺癌

12. 各地區多重檢測免疫檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

13. 多重檢測免疫檢測市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國多重檢測免疫檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • Bio-Rad Laboratories, Inc.
    • Becton, Dickinson and Company
    • PerkinElmer, Inc.
    • Luminex Corporation
    • QIAGEN NV
    • Bio-Techne Corporation
    • Meso Scale Diagnostics, LLC
    • Olink Proteomics AB
Product Code: MRR-FF012EDC38B1

The Multiplex Detection Immunoassays Market is projected to grow by USD 3.91 billion at a CAGR of 7.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.25 billion
Estimated Year [2025] USD 2.41 billion
Forecast Year [2032] USD 3.91 billion
CAGR (%) 7.12%

An authoritative introduction to multiplex detection immunoassays framing technological convergence, clinical applications, and stakeholder expectations shaping strategic priorities

The multiplex detection immunoassays landscape has evolved into a cornerstone of modern translational research, clinical diagnostics, and therapeutic development. Advances in assay miniaturization, reagent chemistry, and data analytics have collectively enabled simultaneous measurement of multiple analytes from minimal sample volumes, improving throughput while preserving biological context. These technologies are increasingly integral to biomarker discovery, immunoprofiling, and multiplexed clinical panels where multidimensional readouts can refine diagnostic specificity and stratify patient populations for targeted therapies.

Today's users expect platforms that bridge rigorous analytical performance with operational efficiency. This expectation has driven instrument vendors, reagent suppliers, and service providers to iterate on assay formats and workflow integration, focusing on robustness, reproducibility, and scalability. Simultaneously, the emphasis on open data standards and interoperability has broadened the role of software and services that translate raw assay signals into clinically meaningful insights. As a result, the sector now sits at the intersection of diagnostics, life sciences research, and precision medicine, serving a diverse set of end users including academic research centers, contract research organizations, clinical laboratories, and pharmaceutical and biotechnology firms.

Given these dynamics, stakeholders must balance technical performance with commercialization considerations, regulatory pathways, and evolving application portfolios. The introduction sets the stage for a detailed examination of technological trajectories, segmentation nuances, regulatory and trade headwinds, and regional market dynamics that together shape near-term priorities and long-term strategic choices for organizations operating in this field.

How technological convergence, workflow integration, and ecosystem partnerships are redefining competitive dynamics and adoption trajectories in multiplex immunoassays

Over the past five years the multiplex detection immunoassays domain has undergone transformative shifts driven by converging technological innovations and changing end-user demands. Transition from single-analyte assays toward high-content bead, planar array, and microarray formats has accelerated adoption across discovery and clinical settings. Improvements in flow cytometry-based systems and bead-based platforms have enhanced sensitivity and dynamic range, while microarray and planar approaches have allowed denser probe architectures to capture broader analyte signatures within constrained sample volumes.

Parallel to hardware advances, the maturation of data analysis software and cloud-enabled workflows has made complex multiplex data more accessible to non-specialist laboratories. These software enhancements underpin reproducible analytics, automated quality control, and streamlined reporting-critical enablers for routine clinical adoption. Regulatory expectations have also shifted to emphasize assay validation pathways and traceability, prompting vendors to invest in higher-quality reagents, standardized protocols, and comprehensive documentation.

Another notable shift is the increasing prominence of partnerships and platform ecosystems. Instrument manufacturers are aligning with reagent providers, software developers, and contract research organizations to deliver integrated solutions that reduce time-to-result and lower operational barriers. This collaborative model supports rapid assay development and facilitates deployment across diverse end users, from academic labs to diagnostic service providers. Collectively, these shifts are reshaping competitive dynamics and creating new pathways for differentiation centered on end-to-end workflow value rather than singular component performance.

Assessing how tariff adjustments through 2025 have reshaped procurement strategies, supply chain resilience, and manufacturing localization decisions across the immunoassay value chain

The landscape of trade measures and tariff adjustments introduced by the United States through 2025 has introduced a layer of complexity for suppliers and end users in the multiplex detection immunoassays value chain. Tariff changes have affected the relative cost structure for imported instruments, assay kits, and critical raw materials, influencing procurement strategies across manufacturers, distributors, and clinical laboratories. Suppliers with geographically diversified manufacturing and sourcing strategies have fared better in mitigating immediate cost disruptions, while those reliant on single-region supply lines have faced operational pressure to rework supplier contracts and revisit pricing models.

These tariff-related dynamics have also prompted firms to accelerate localization strategies for production and assembly, enabling closer control over customs classifications and reducing exposure to fluctuating import duties. In response, some companies have implemented hybrid sourcing models that combine regional manufacturing for critical components with centralized high-tech assembly to preserve economies of scale. At the same time, contract research and diagnostic service providers have adjusted purchasing cadences and inventory policies to hedge against short-term cost volatility and delivery uncertainty.

Regulatory and procurement teams have increasingly emphasized total landed cost assessment and supplier resilience when evaluating capital equipment and reagent purchases. This has led to a greater focus on multi-year service agreements, modular upgrade paths for instruments, and supplier warranties that transfer certain risks back to manufacturers. In aggregate, the tariff environment through 2025 has elevated the strategic importance of supply chain configuration, procurement flexibility, and localized support capabilities for organizations operating across the multiplex immunoassays ecosystem.

Comprehensive segmentation analysis linking technology formats, product portfolios, end-user requirements, and clinical applications to inform prioritization and go-to-market choices

Understanding the modular architecture of the multiplex detection immunoassays market requires a clear articulation of the primary technology, product, end-user, and application dimensions that define competitive and use-case boundaries. From a technology perspective, distinctions between bead-based immunoassays, flow cytometry-based immunoassays, microarray-based immunoassays, and planar array immunoassays are fundamental because each format delivers a different balance of throughput, sensitivity, multiplexing density, and workflow compatibility. These technological choices in turn influence product design and downstream service requirements.

When examining products, the market segments into instruments, kits and reagents, and software and services. Instruments encompass analyzers, flow cytometers, and readers that form the hardware backbone of multiplex workflows. Kits and reagents include assay beads, detection antibodies, microarrays, and multiplex assay kits that determine the biochemical performance and specificity of assays. Software and services cover assay development services, data analysis software, and support and maintenance offerings that enable standardized operations and post-sale value capture. Each product category interacts with technology formats differently and necessitates tailored commercialization models.

End users of multiplex platforms span academic and research institutes, contract research organizations, hospitals and diagnostic laboratories, and pharmaceutical and biotechnology companies. These diverse user groups have distinct purchasing rationales, validation expectations, and throughput requirements, which influence product roadmaps and go-to-market approaches. Application areas further refine deployment priorities, with use cases across autoimmune conditions, cardiovascular disease, infectious diseases, neurological disorders, and oncology. Within these applications, subdomains such as inflammatory bowel disease, rheumatoid arthritis, Alzheimer's disease, multiple sclerosis, breast cancer, and viral infections like hepatitis and influenza dictate specific panel compositions, regulatory considerations, and clinical validation pathways. Mapping product capabilities to these segmented needs is essential for prioritizing development investments and commercial engagement strategies.

Key regional dynamics and strategic considerations across the Americas, Europe Middle East and Africa, and Asia-Pacific that influence adoption, distribution, and regulatory pathways

Regional dynamics exert a profound influence on technology adoption, distribution models, and regulatory pathways for multiplex detection immunoassays, with distinctive patterns emerging across the Americas, Europe Middle East and Africa, and Asia-Pacific. In the Americas, strong academic networks, established clinical laboratory infrastructure, and a robust biotech sector drive early adoption of novel assays and integrated platforms. Procurement practices tend to favor validated workflows and extensive post-sale support, which incentivizes vendors to offer comprehensive service packages and localized technical assistance.

Europe Middle East and Africa present a heterogeneous environment where regulatory harmonization efforts in some jurisdictions coexist with fragmented reimbursement and procurement systems in others. This complexity amplifies the importance of tailored market entry strategies, partnerships with regional distributors, and investments in regulatory and clinical evidence generation that meet diverse national requirements. In contrast, Asia-Pacific markets exhibit rapid uptake of cost-effective platforms and point-of-care-enabling technologies, supported by growing domestic manufacturing capabilities and public-private collaborations that accelerate translational research and clinical deployment.

Across all regions, regional supply chain considerations, tariff regimes, and local validation expectations shape vendor strategies. Companies seeking to scale across multiple regions must reconcile variant regulatory demands with the need for consistent assay performance and interoperable data outputs. Consequently, regional market planning must integrate clinical engagement, distribution logistics, and post-market surveillance mechanisms to ensure sustainable adoption and long-term product stewardship.

Insights into company strategies, partnership models, and capability investments that are driving differentiation and creating integrated value propositions in the sector

The competitive landscape in multiplex detection immunoassays includes a mix of instrument manufacturers, reagent specialists, software innovators, and integrated solution providers that compete and collaborate across the value chain. Leading instrument providers differentiate on analytical performance, throughput, and ease of integration, while reagent and kit suppliers focus on assay specificity, lot-to-lot consistency, and regulatory documentation to support clinical and research use. Software vendors and service providers are increasingly central, transforming raw assay output into validated, reproducible insights and enabling scalable deployment through cloud analytics and robust quality management modules.

Partnership strategies are a recurring theme among successful companies. Collaborations between instrument manufacturers and reagent developers accelerate time-to-market for validated panels, while alliances with contract research organizations facilitate early-stage assay validation and broader clinical exposure. Strategic acquisitions have also played a role, enabling companies to vertically integrate critical capabilities such as proprietary chemistries, data analysis toolkits, and global distribution networks. Additionally, commercial models are diversifying, with subscription and service-based offerings complementing traditional capital equipment sales to spread adoption risk and create recurring revenue streams.

Operationally, successful firms emphasize regulatory readiness, supply chain flexibility, and comprehensive customer support. Investments in standardized quality systems, global service footprints, and local manufacturing or assembly capabilities help mitigate trade and logistics risks. Looking forward, companies that can demonstrate end-to-end value-combining robust instrumentation, high-quality reagents, and software-enabled analytics-will be best positioned to capture adoption when customers prioritize validated, workflow-oriented solutions over standalone components.

Actionable strategic imperatives for leaders to enhance platform modularity, supply chain resilience, regulatory readiness, and partnership-led commercialization

Industry leaders should pursue a deliberate set of actions to strengthen competitive positioning, accelerate adoption, and manage operational risk. First, prioritize modular platform development that enables incremental upgrades and cross-compatibility across assay formats; this reduces customer switching costs and increases lifetime value. Coupling modular hardware with validated reagent panels and interoperable data analysis software creates compelling, differentiated solutions that align with end-user workflows.

Second, fortify supply chain resilience by diversifying component sources and exploring regional manufacturing or assembly hubs to mitigate tariff exposure and logistics disruptions. Embedding dual sourcing for critical reagents and establishing strategic buffer inventories in key geographies will decrease lead-time vulnerability. Third, invest in regulatory and clinical evidence generation early in development cycles. Establish clear validation roadmaps that address jurisdictional differences and prioritize high-impact use cases, such as oncology and infectious disease panels, where clinical utility is demonstrable and adoption thresholds are clearer.

Fourth, cultivate ecosystem partnerships with reagent developers, software providers, clinical labs, and contract research organizations to accelerate assay validation and expand addressable applications. Co-development agreements and revenue-sharing models can help scale adoption while sharing development risk. Fifth, adopt flexible commercial models that blend capital sales with subscription-based analytics and service contracts, thereby aligning vendor incentives with successful long-term outcomes for customers. Finally, emphasize workforce training and customer support infrastructure to ensure that end users derive consistent, reproducible performance from multiplex platforms, reinforcing trust and reducing downstream support costs.

A rigorous mixed-methods research approach integrating primary expert interviews, secondary literature validation, and cross-regional triangulation to support defensible insights

The research underpinning these insights combined a layered methodological approach to ensure robust, reproducible conclusions. A comprehensive review of primary technical literature, regulatory guidance, and publicly available clinical validation studies established the evidence base for technology performance characteristics and application suitability. This secondary research was complemented by structured primary interviews with subject matter experts, including laboratory directors, assay development scientists, procurement leads, and senior executives from platform, reagent, and software providers to capture operational realities and strategic intent.

Data triangulation was employed to reconcile qualitative insights with documented product specifications, regulatory filings, and peer-reviewed study results. The methodological framework emphasized cross-validation of claims, focusing on repeatable findings such as assay workflow dependencies, reagent stability considerations, and software integration challenges. To ensure relevance across geographies, regional experts were consulted to identify jurisdiction-specific regulatory expectations, procurement practices, and supply chain vulnerabilities.

Limitations of the methodology are acknowledged transparently. Certain proprietary performance metrics and internal procurement data were unavailable for direct verification, and interviews reflect expert judgment which can vary by institution type and use case. Nonetheless, the combined use of primary expert input, secondary literature validation, and cross-regional perspective building provides a high-confidence foundation for the strategic and operational recommendations presented. Where appropriate, the report highlights areas where further primary data collection or controlled comparative studies would strengthen conclusions.

Concluding synthesis identifying the decisive combination of validated performance, evidence generation, and operational resilience required for sustainable adoption of multiplex solutions

The cumulative analysis reveals a field at the nexus of technological maturation, clinical need, and commercial reinvention. Multiplex detection immunoassays have transitioned from niche research tools to broadly applicable platforms capable of supporting discovery, translational research, and increasingly rigorous clinical applications. Technological diversity-spanning bead-based, flow cytometry-based, microarray-based, and planar array approaches-offers pathways to tailor solutions by throughput, sensitivity, and sample constraints, while product segmentation across instruments, kits and reagents, and software and services delineates clear commercialization levers.

External forces such as tariff developments and regional regulatory variation have elevated supply chain strategy and localized validation as determinants of near-term competitiveness. At the same time, software-driven analytics and service models are unlocking new routes to value capture by transforming complex assay outputs into actionable, reproducible insights for clinicians and researchers. Companies that integrate platform performance with end-to-end support, evidence generation, and flexible commercial models will be better positioned to win in diverse end-user environments ranging from academic labs to clinical diagnostic settings.

In sum, success will favor organizations that balance innovation with operational rigor: those that can demonstrate validated clinical utility, ensure consistent reagent quality, provide interoperable analytics, and maintain resilient supply and support systems. This balanced approach will enable stakeholders to capitalize on the promise of multiplex detection technologies while managing the practical challenges of deployment and scale.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of microfluidic platforms for high-throughput multiplex immunoassays in point-of-care diagnostics
  • 5.2. Adoption of novel fluorescent barcoding techniques for simultaneous detection of multiple cytokines in clinical research
  • 5.3. Emergence of AI-driven data analysis software to enhance multiplex assay interpretation and predictive biomarker discovery
  • 5.4. Development of bead-based multiplex immunoassays using magnetic nanoparticles for rapid pathogen screening in food safety applications
  • 5.5. Growing emphasis on standardized calibration methods to improve inter-lab reproducibility of multiplex assay results across platforms
  • 5.6. Utilization of digital ELISA technology for ultrasensitive detection of low-abundance protein biomarkers in multiplex panels
  • 5.7. Expansion of single-cell multiplex immunoassays enabling comprehensive immune profiling in autoimmune disease research
  • 5.8. Integration of smartphone-based imaging modules for portable multiplex immunoassay readouts in remote healthcare settings
  • 5.9. Collaboration between biotech companies and academic institutions to develop universal assay platforms compatible with diverse analyte panels
  • 5.10. Increasing regulatory focus on multiplex assay validation standards to ensure clinical utility and patient safety

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiplex Detection Immunoassays Market, by Technology

  • 8.1. Bead Based Immunoassays
  • 8.2. Flow Cytometry Based Immunoassays
  • 8.3. Microarray Based Immunoassays
  • 8.4. Planar Array Immunoassays

9. Multiplex Detection Immunoassays Market, by Product

  • 9.1. Instruments
    • 9.1.1. Analyzers
    • 9.1.2. Flow Cytometers
    • 9.1.3. Readers
  • 9.2. Kits And Reagents
    • 9.2.1. Assay Beads
    • 9.2.2. Detection Antibodies
    • 9.2.3. Microarrays
    • 9.2.4. Multiplex Assay Kits
  • 9.3. Software & Services
    • 9.3.1. Assay Development Services
    • 9.3.2. Data Analysis Software
    • 9.3.3. Support & Maintenance

10. Multiplex Detection Immunoassays Market, by End User

  • 10.1. Academic And Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Hospitals And Diagnostic Laboratories
  • 10.4. Pharmaceutical And Biotechnology Companies

11. Multiplex Detection Immunoassays Market, by Application

  • 11.1. Autoimmune
    • 11.1.1. Inflammatory Bowel Disease
    • 11.1.2. Rheumatoid Arthritis
    • 11.1.3. Systemic Lupus Erythematosus
  • 11.2. Cardiovascular
    • 11.2.1. Atherosclerosis
    • 11.2.2. Heart Failure
    • 11.2.3. Hypertension
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
      • 11.3.1.1. E Coli
      • 11.3.1.2. Salmonella
      • 11.3.1.3. Tuberculosis
    • 11.3.2. Parasitic Infections
      • 11.3.2.1. Malaria
      • 11.3.2.2. Schistosomiasis
      • 11.3.2.3. Toxoplasmosis
    • 11.3.3. Viral Infections
      • 11.3.3.1. Hepatitis
      • 11.3.3.2. HIV
      • 11.3.3.3. Influenza
  • 11.4. Neurological
    • 11.4.1. Alzheimer's Disease
    • 11.4.2. Multiple Sclerosis
    • 11.4.3. Parkinson's Disease
  • 11.5. Oncology
    • 11.5.1. Breast Cancer
    • 11.5.2. Colorectal Cancer
    • 11.5.3. Lung Cancer
    • 11.5.4. Prostate Cancer

12. Multiplex Detection Immunoassays Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Multiplex Detection Immunoassays Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Multiplex Detection Immunoassays Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Thermo Fisher Scientific Inc.
    • 15.3.2. Merck KGaA
    • 15.3.3. Bio-Rad Laboratories, Inc.
    • 15.3.4. Becton, Dickinson and Company
    • 15.3.5. PerkinElmer, Inc.
    • 15.3.6. Luminex Corporation
    • 15.3.7. QIAGEN N.V.
    • 15.3.8. Bio-Techne Corporation
    • 15.3.9. Meso Scale Diagnostics, LLC
    • 15.3.10. Olink Proteomics AB

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. MULTIPLEX DETECTION IMMUNOASSAYS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. MULTIPLEX DETECTION IMMUNOASSAYS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTIPLEX DETECTION IMMUNOASSAYS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BEAD BASED IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETRY BASED IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAY BASED IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PLANAR ARRAY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY FLOW CYTOMETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY READERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY KITS AND REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY BEADS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DETECTION ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MICROARRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MULTIPLEX ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ASSAY DEVELOPMENT SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SUPPORT & MAINTENANCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY ATHEROSCLEROSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEART FAILURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY E COLI, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SALMONELLA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY MALARIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY TOXOPLASMOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HEPATITIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MULTIPLEX DETECTION IMMUNOASSAYS MARKET SIZE, BY HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MULTIPLEX